Peramivir
Mechanism :
Peramivir, a cyclopentane analogue, selectively inhibits the influenza virus neuraminidase enzyme, preventing the release of viral particles from infected cells.
Indication :
- Treatment of acute uncomplicated influenza in patients’ ≥2 years of age who have been symptomatic ≤2 days.
Contraindications :
Serious hypersensitivity or anaphylaxis to peramivir or any component of the formulation.
Dosing :
2 to 12 years:
12 mg/kg IV as a single dose; Maximum dose: 600 mg.
≥13 years:
600 mg as a single dose IV in uncomplicated and 600 mg once daily for 5 to 10 days in hospitalized, high risk patients.
Adverse Effect :
Hypertension, insomnia, hyperglycemia, diarrhea, constipation, vomiting, proteinuria, neutropenia, increased serum AST, ALT & CPK, fever.
Interaction :
Influenza Virus Vaccine (Live/Attenuated): Antiviral Agents may diminish the therapeutic effect of Influenza Virus Vaccine.
Hepatic Dose :
No dose adjustment recommended.